{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T04:40:11Z","timestamp":1776487211911,"version":"3.51.2"},"reference-count":25,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.7101-26","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T22:09:50Z","timestamp":1776118190000},"source":"Crossref","is-referenced-by-count":0,"title":["The urinary Isoxanthopterin\/pterin Ratio Reflects Mild Fasting Hyperglycemia in Obese Patients with Type 2 Diabetes Mellitus: An Exploratory Cross-sectional Study"],"prefix":"10.2169","author":[{"given":"Rei","family":"Chinen","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology, Second Department of Internal Medicine, Graduate School of Medicine, University of the Ryukyus, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Shirakura","sequence":"additional","affiliation":[{"name":"Teijin Pharma Limited, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoma","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology, Second Department of Internal Medicine, Graduate School of Medicine, University of the Ryukyus, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Ishiki","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology, Second Department of Internal Medicine, Graduate School of Medicine, University of the Ryukyus, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuko","family":"Tamaki","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology, Second Department of Internal Medicine, Graduate School of Medicine, University of the Ryukyus, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken-Ichiro","family":"Honma","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology, Second Department of Internal Medicine, Graduate School of Medicine, University of the Ryukyus, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chie","family":"Horiguchi","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology, Second Department of Internal Medicine, Graduate School of Medicine, University of the Ryukyus, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsugumi","family":"Uema","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology, Second Department of Internal Medicine, Graduate School of Medicine, University of the Ryukyus, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koshi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Public Health and Epidemiology Graduate School of Medicine, University of the Ryukyus, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Masuzaki","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology, Second Department of Internal Medicine, Graduate School of Medicine, University of the Ryukyus, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Kelley EE. Dispelling dogma and misconceptions regarding the most pharmacologically targetable source of reactive species in inflammatory disease, xanthine oxidoreductase. Arch Toxicol 89: 1193-1207, 2015.","DOI":"10.1007\/s00204-015-1523-8"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol 555: 589-606, 2004.","DOI":"10.1113\/jphysiol.2003.055913"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Jomova K, Alomar SY, Alwasel SH, Nepovimova E, Kuca K, Valko M. Several lines of antioxidant defense against oxidative stress: antioxidant enzymes, nanomaterials with multiple enzyme-mimicking activities, and low-molecular-weight antioxidants. Arch Toxicol 98: 1323-1367, 2024.","DOI":"10.1007\/s00204-024-03696-4"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Sunagawa S, Shirakura T, Hokama N, et al. Activity of xanthine oxidase in plasma correlates with indices of insulin resistance and liver dysfunction in patients with type 2 diabetes mellitus and metabolic syndrome: A pilot exploratory study. J Diabetes Investig 10: 94-103, 2019.","DOI":"10.1111\/jdi.12870"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Sheehan JP. Fasting hyperglycemia: etiology, diagnosis, and treatment. Diabetes Technol Ther 6: 525-533, 2004.","DOI":"10.1089\/1520915041705910"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 39: 1577-1583, 1996.","DOI":"10.1007\/s001250050617"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Hokama N, Shirakura T, Sunagawa S, et al. A pilot assessment of xanthine oxidase activity in plasma from patients with hematological malignancies using a highly sensitive assay. Hematol Oncol 37: 527-530, 2019.","DOI":"10.1002\/hon.2659"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Yamamoto T, Moriwaki Y, Takahashi S. Effect of ethanol on metabolism of purine bases (hypoxanthine, xanthine, and uric acid). Clin Chim Acta 356: 35-57, 2005.","DOI":"10.1016\/j.cccn.2005.01.024"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Corso LML, Wing RR, Tate DF, Espeland MA, Blanchard BE, McCaffery JM. Uric acid as a predictor of weight gain and cardiometabolic health in the Study of Novel Approaches to Weight Gain Prevention (SNAP) study. Int J Obes (Lond) 46: 1556-1559, 2022.","DOI":"10.1038\/s41366-022-01131-1"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Lytvyn Y, Perkins BA, Cherney DZ. Uric acid as a biomarker and a therapeutic target in diabetes. Can J Diabetes 39: 239-246, 2015.","DOI":"10.1016\/j.jcjd.2014.10.013"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Blau N, de Klerk JB, Th\u00f6ny B, et al. Tetrahydrobiopterin loading test in xanthine dehydrogenase and molybdenum cofactor deficiencies. Biochem Mol Med 58: 199-203, 1996.","DOI":"10.1006\/bmme.1996.0049"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Li Q, Wei S, Wu D, Wen C, Zhou J. Urinary Metabolomics Study of Patients with Gout Using Gas Chromatography-Mass Spectrometry. Biomed Res Int 2018: 3461572, 2018.","DOI":"10.1155\/2018\/3461572"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Lindsay A, McCourt PM, Karachunski P, Lowe DA, Ervasti JM. Xanthine oxidase is hyper-active in Duchenne muscular dystrophy. Free Radic Biol Med 129: 364-371, 2018.","DOI":"10.1016\/j.freeradbiomed.2018.10.404"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Ma Y, Burton C. Pteridine detection in urine: the future of cancer diagnostics? Biomark Med 7: 679-681, 2013.","DOI":"10.2217\/bmm.13.88"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Ko\u015bli\u0144ski P, Pluskota R, M\u0105dra-Gackowska K, et al. Comparison of Pteridine Normalization Methods in Urine for Detection of Bladder Cancer. Diagnostics (Basel) 10: 612, 2020.","DOI":"10.3390\/diagnostics10090612"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Otaki Y, Watanabe T, Kinoshita D, et al. Association of plasma xanthine oxidoreductase activity with severity and clinical outcome in patients with chronic heart failure. Int J Cardiol 228: 151-157, 2017.","DOI":"10.1016\/j.ijcard.2016.11.077"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. \u00d6zer Y, Cansever M, Turan H, et al. Pteridine and tryptophan pathways in children with type 1 diabetes: Isoxanthopterin as an indicator of endothelial dysfunction. J Pharm Biomed Anal 243: 116072, 2024.","DOI":"10.1016\/j.jpba.2024.116072"},{"key":"18","unstructured":"18. Japan Society for the Study of Obesity. Guidelines for the management of obesity disease 2022ed. Life Science Publishing CO., Ltd., Tokyo, 2022."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Walter R, Blau N, Schaffner A, et al. Inhalation of the nitric oxide synthase cofactor tetrahydrobiopterin in healthy volunteers. Am J Respir Crit Care Med 156: 2006-2010, 1997.","DOI":"10.1164\/ajrccm.156.6.96-12084"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 48: 452-458, 2013.","DOI":"10.1038\/bmt.2012.244"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Nystr\u00f6m T, Nygren A, Sj\u00f6holm A. Tetrahydrobiopterin increases insulin sensitivity in patients with type 2 diabetes and coronary heart disease. Am J Physiol Endocrinol Metab 287: E919-E925, 2004.","DOI":"10.1152\/ajpendo.00046.2004"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Di Bonito P, Valerio G, Licenziati MR, et al. Uric acid, impaired fasting glucose and impaired glucose tolerance in youth with overweight and obesity. Nutr Metab Cardiovasc Dis 31: 675-680, 2021.","DOI":"10.1016\/j.numecd.2020.10.007"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Usui R, Hamamoto Y, Imura M, et al. Differential effects of imeglimin and metformin on insulin and incretin secretion-An exploratory randomized controlled trial. Diabetes Obes Metab 27: 856-865, 2025.","DOI":"10.1111\/dom.16086"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Cuatrecasas G, De Cabo F, Coves MJ, et al. Dapagliflozin added to metformin reduces perirenal fat layer in type 2 diabetic patients with obesity. Sci Rep 14: 10832, 2024.","DOI":"10.1038\/s41598-024-61590-6"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Bril F, Kalavalapalli S, Clark VC, et al. Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes. Clin Gastroenterol Hepatol 16: 558-566.e552, 2018.","DOI":"10.1016\/j.cgh.2017.12.001"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7101-26\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T03:51:36Z","timestamp":1776484296000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7101-26\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":25,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7101-26","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"7101-26"}}